CSIMarket
 


Cyclo Therapeutics Inc   (CYTH)
Other Ticker:  
 

Cyclo Therapeutics Inc 's Leverage Ratio

CYTH's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 12.91%, Leverage Ratio fell to 1.57, above the Cyclo Therapeutics Inc 's average Leverage Ratio.

Within Biotechnology & Pharmaceuticals industry in the forth quarter 2023, 49 other companies have achieved lower Leverage Ratio than Cyclo Therapeutics Inc in the IV Quarter 2023. While Leverage Ratio total ranking has deteriorated compared to the third quarter 2023 from 0 to 1499 .

Explain Leverage Ratio?
Who are CYTH Customers?
What are CYTH´s Total Liabilities?


CYTH Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change 547.61 % - - - -95.31 %
Y / Y Total Liabilities Change 114.25 % 130.11 % 190.54 % 56.65 % -9.11 %
Leverage Ratio MRQ 1.57 - - - 4.74
CYTH's Total Ranking # 1499 # 0 # 0 # 0 # 3324
Seq. Equity Change - - - - -86.91 %
Seq. Total Liabilities Change 12.91 % 8.66 % 35.59 % 28.79 % 21.27 %



Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 50
Healthcare Sector # 325
Overall Market # 1499


Leverage Ratio Statistics
High Average Low
7.66 1.02 0.09
(Sep 30 2018)   (Mar 31 2017)




Financial Statements
Cyclo Therapeutics Inc 's Equity $ 5 Millions Visit CYTH's Balance sheet
Cyclo Therapeutics Inc 's Total Liabilities $ 7 Millions Visit CYTH's Balance sheet
Source of CYTH's Sales Visit CYTH's Sales by Geography


Cumulative Cyclo Therapeutics Inc 's Leverage Ratio

CYTH's Leverage Ratio for the trailling 12 Months

CYTH Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth 547.61 % - - - -95.31 %
Y / Y Total Liabilities TTM Growth 114.25 % 130.11 % 190.54 % 56.65 % -9.11 %
Leverage Ratio TTM 13.83 - 3.82 0.83 0.39
Total Ranking TTM # 140 # 0 # 32 # 7 # 4
Seq. Equity TTM Growth - - - - -86.91 %
Seq. Total Liabilities TTM Growth 12.91 % 8.66 % 35.59 % 28.79 % 21.27 %


On the trailing twelve months basis Due to the net new borrowings of 12.91% during the trailing twelve months finishing in the IV Quarter 2023, cumulativeLeverage Ratio decreased to 13.83, above the Cyclo Therapeutics Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 9, during the past 12 months, other companies have achieved lower Leverage Ratio than Cyclo Therapeutics Inc . While Leverage Ratio total ranking has deteriorated during the twelve months ending in the IV Quarter 2023, compared to the prior period, from 0 to 140.

Explain Leverage Ratio?
Who are CYTH Customers?
What are CYTH´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 10
Healthcare Sector # 62
Within the Market # 140


trailing twelve months Leverage Ratio Statistics
High Average Low
17.13 2 0.22
(Jun 30 2020)   (Sep. 30, 2015)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Equity
Curis Inc   2.86 $ 56.307  Millions$ 19.670  Millions
Valneva Se  2.59 $ 371.633  Millions$ 143.637  Millions
Cyclo Therapeutics Inc   1.57 $ 7.457  Millions$ 4.757  Millions
Gilead Sciences Inc   1.43 $ 32,622.000  Millions$ 22,749.000  Millions
Protalix Biotherapeutics inc   1.38 $ 46.244  Millions$ 33.569  Millions
Meiragtx Holdings Plc  1.36 $ 188.567  Millions$ 138.177  Millions
Adma Biologics Inc   1.34 $ 181.282  Millions$ 135.206  Millions
Pharmacyte Biotech Inc   1.27 $ 39.984  Millions$ 31.375  Millions
Cel sci Corporation  1.27 $ 16.060  Millions$ 12.650  Millions
Sangamo Therapeutics Inc   0.99 $ 82.433  Millions$ 82.887  Millions
Century Therapeutics inc   0.95 $ 175.941  Millions$ 184.750  Millions
Coeptis Therapeutics Holdings Inc   0.85 $ 3.658  Millions$ 4.314  Millions
Biogen Inc   0.81 $ 12,045.400  Millions$ 14,799.400  Millions
Elevation Oncology inc   0.63 $ 34.282  Millions$ 54.809  Millions
Vaxart Inc   0.59 $ 34.025  Millions$ 57.805  Millions
Vericel Corporation  0.57 $ 127.705  Millions$ 225.952  Millions
C4 Therapeutics Inc   0.53 $ 130.337  Millions$ 246.114  Millions
Immunocore Holdings Plc  0.52 $ 192.137  Millions$ 368.843  Millions
Prime Medicine Inc   0.46 $ 60.780  Millions$ 133.071  Millions
Neurocrine Biosciences Inc   0.46 $ 1,019.400  Millions$ 2,232.000  Millions
Qiagen N v   0.44 $ 1,692.857  Millions$ 3,807.764  Millions
Editas Medicine Inc   0.43 $ 150.056  Millions$ 349.097  Millions
Recursion Pharmaceuticals Inc   0.41 $ 190.263  Millions$ 463.436  Millions
Sophia Genetics Sa  0.36 $ 54.714  Millions$ 151.442  Millions
Black Diamond Therapeutics Inc   0.36 $ 41.831  Millions$ 116.736  Millions
Passage Bio inc   0.35 $ 39.262  Millions$ 111.283  Millions
Tarsus Pharmaceuticals Inc   0.35 $ 68.503  Millions$ 196.988  Millions
Moderna Inc   0.33 $ 4,572.000  Millions$ 13,854.000  Millions
Scholar Rock Holding Corp  0.33 $ 74.017  Millions$ 225.218  Millions
Iovance Biotherapeutics Inc   0.32 $ 187.961  Millions$ 584.613  Millions

Date modified: 2024-03-18T20:45:52+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com